)
Visual
test
SELLAS Life Sciences Group
SELLAS Life Sciences Group (SLS) investor relations material
SELLAS Life Sciences Group Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Mar, 2026
Executive summary
Advanced pivotal Phase 3 REGAL trial of GPS in AML, with final analysis pending upon reaching 80 events.
First patient dosed in Phase 2 trial of SLS009 in newly diagnosed AML; positive Phase 2 data in relapsed/refractory AML presented at ASH 2025.
Entered European collaboration to expand SLS009 clinical program, with enrollment of 40 patients anticipated in Q2 2026.
Financial highlights
Cash and cash equivalents totaled $71.8 million as of December 31, 2025; an additional $42.6 million received in Q1 2026 from warrant exercises.
Research and development expenses were $16.0 million for 2025, down from $19.1 million in 2024.
General and administrative expenses were $12.3 million for 2025, slightly down from $12.4 million in 2024.
Net loss for 2025 was $26.9 million, or $0.25 per share, compared to $30.9 million, or $0.50 per share, in 2024.
Received $67.2 million in gross proceeds from warrant exercises in 2025.
Outlook and guidance
2026 expected to be a pivotal year with REGAL trial final analysis and expansion of SLS009 into earlier AML treatment settings.
Additional clinical milestones anticipated, including European patient enrollment and further data disclosures.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SELLAS Life Sciences Group
- REGAL Phase 3 interim analysis in AML will guide next steps after IDMC review in January 2025.SLS
Study Update11 Jan 2026 - Late-stage cancer drug developer registers resale of 19.7M shares tied to new warrant inducement.SLSRegistration Filing16 Dec 2025
- Six key proposals, including director elections and compensation, headline the 2025 virtual meeting.SLSProxy Filing2 Dec 2025
- Key votes include director elections, auditor ratification, and ESPP share increase.SLSProxy Filing2 Dec 2025
- Auditor change to Baker Tilly for 2025; prior votes valid, no new proxy cards needed.SLSProxy Filing2 Dec 2025
- Net loss narrowed, cash reserves grew, and key oncology trials advanced amid ongoing risks.SLSQ3 202512 Nov 2025
- GPS and SLS009 advance as differentiated AML therapies, supported by strong data and financing.SLSR&D Day 20255 Nov 2025
- Net loss narrowed, clinical milestones approach, but liquidity and funding concerns remain.SLSQ3 202413 Oct 2025
- Net loss narrowed, but new funding is needed as clinical programs advance.SLSQ2 202512 Aug 2025
Next SELLAS Life Sciences Group earnings date
Q1 202611 May, 2026
SELLAS Life Sciences Group
Next SELLAS Life Sciences Group earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage